Nausea and vomiting · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in adverse event (nausea/ vomiting) compared with observation alone (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in progression‐free survival compared with observation alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (flu‐like symptoms) compared with observation alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (fatigue) compared with observation alone (low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review
Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…
Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).
1 finding from 1 review
Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T1‐hypointense lesion load · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review